OCC

Orthocell

Pharmaceuticals, Biotechnology & Life Sciences

Orthocell is a leader in the regenerative medicine sector, focusing on innovative treatments for chronic degenerative diseases and injuries. The company specializes in developing collagen medical devices and cell therapies that leverage the body's natural repair mechanisms. Orthocell's products are designed to enhance surgical repair and promote tissue regeneration, positioning it as a pioneer in ...

Regenerative Medicine

Biotechnology

Orthopedic Surgery

Cell Therapy

Shorted

short percentage0.64%

reported shorts1.7M

shares on issue271.308M

About

website

orthocell.com.au

industry

Pharmaceuticals, Biotechnology & Life Sciences

address

Building 191 Murdoch University, South Street, MURDOCH, WA, AUSTRALIA, 6150

Connect

Key Metrics

market cap

$255.03M

eps$-0.04

More Pharmaceuticals, Biotechnology & Life Sciences Stocks

Other shorted stocks in this sector

View all stocks in this industry

Short Position Trends

Track bearish sentiment and short interest over time

Historical Price Data

View stock price movements, volume, and trading patterns

Industry & Focus

Regenerative Medicine

Biotechnology

Orthopedic Surgery

Cell Therapy

Collagen Devices

Company Overview

AI-generated company summary

Company History

Orthocell was founded to address the growing need for advanced regenerative medicine solutions. Over the years, the company has evolved by developing proprietary technologies such as the SMRT™ manufacturing process for collagen devices. Major milestones include the commercialization of autologous tendon therapy and the expansion into nerve and bone repair markets. Orthocell continues to innovate with a focus on improving patient outcomes and expanding its product portfolio.

Competitive Advantages

Orthocell's competitive advantages include its proprietary SMRT™ manufacturing process, which preserves the natural collagen structure in medical devices, and its focus on autologous cell therapies that reduce the risk of rejection. Additionally, the company's expertise in developing products that integrate seamlessly with the body's natural repair processes sets it apart in the regenerative medicine market.

Risk Factors

•Regulatory approval challenges
•Competition from established biotechnology firms
•Dependence on successful commercialization of new therapies

Recent Developments

Last 6 months

In the past six months, Orthocell has focused on expanding its product offerings and enhancing its collagen medical device platform to support surgical repair of bone and soft tissue.

Key People

Leadership team at Orthocell

Mr Paul Anderson

Chief Executive Officer

Paul Anderson serves as the Chief Executive Officer and Managing Director, leading Orthocell's strategic direction and operations.

Mr Jim Piper

Chief Financial Officer

Jim Piper is the Chief Financial Officer, responsible for overseeing the financial strategy and operations of Orthocell.